Silence Therapeutics
SLN
54 hedge funds and large institutions have $96.4M invested in Silence Therapeutics in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 15 increasing their positions, 16 reducing their positions, and 7 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.18% less ownership
Funds ownership: 66.02% → 65.84% (-0.18%)
6% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 16
2% less funds holding
Funds holding: 55 → 54 (-1)
11% less capital invested
Capital invested by funds: $108M → $96.4M (-$11.6M)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $6K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$555K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$438K |
| 3 |
BFM
Boothbay Fund Management
New York
|
+$151K |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$151K |
| 5 |
Goldman Sachs
New York
|
+$126K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$591K |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$515K |
| 3 |
Jane Street
New York
|
-$219K |
| 4 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
-$201K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$161K |
SLN Hedge Fund Activity: Q3 2025 in Review
54 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q3 2025, worth a combined $96.4M — down 11% from $108M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of SLN and 6 opened new positions — a net loss of 1 holder — while 16 trimmed existing stakes and 15 added.
The largest buyer was Millennium Management, adding an estimated $555K. The largest seller was BlackRock, cutting an estimated $591K.
- 54 institutional investors held Silence Therapeutics (SLN) as of Q3 2025, down from 55 in Q2 2025.
- Funds reported $96.4M of Silence Therapeutics stock for Q3 2025, down 11% quarter-over-quarter.
- 6 funds opened new Silence Therapeutics positions in Q3 2025 and 7 closed out, a net change of -1 holder.
- The largest Silence Therapeutics buyer in Q3 2025 was Millennium Management, an estimated $555K added.
- The largest Silence Therapeutics seller in Q3 2025 was BlackRock, an estimated $591K sold.
Based on aggregated 13F filings for Q3 2025.